Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, today announced that John Knopf, Ph.D., Chief Executive Officer of Acceleron, will provide a corporate presentation at the 31st Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2013 at 4:30 PM PST (7:30 PM EST) at the Westin St. Francis Hotel in San Francisco, California. This is the fourth time in the past five years that Acceleron has been asked to present at the conference.
Acceleron is a privately-held biopharmaceutical company committed to discover, develop, manufacture and commercialize novel protein therapeutics for orphan diseases and cancer. Acceleron's scientific approach takes advantage of its unique insight to discover first-in-class therapies based on the TGF-β protein superfamily. Acceleron utilizes proven biotherapeutic technologies and capitalizes on the company's internal GMP manufacturing capability to advance its therapeutic programs rapidly and efficiently. The investors in Acceleron include Advanced Technology Ventures, Alkermes, Avalon Ventures, Bessemer Ventures, Celgene, Flagship Ventures, MPM BioEquities, OrbiMed Advisors, Polaris Ventures, QVT Financial, Sutter Hill Ventures and Venrock. For further information on Acceleron, please visit www.acceleronpharma.com.
Acceleron Pharma, Inc.
Steven Ertel, 617-649-9234
Chief Business Officer
Suda Communications LLC
Maureen L. Suda, 585-387-9248
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.